Futura Medical is the developer of innovative sexual health products, including the lead product Eroxon®, focusing on research, development, and commercialization of topically delivered gel formulations in sexual health products.

Futura Medical

Futura Medical plc

Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

Futura Medical | 1,266 followers on LinkedIn. Pharmaceutical company focused on sexual health and pain. | Futura&#39;s innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.

Based in Surrey, UK, the company&#39;s shares trade on the AIM market of the London Stock Exchange. Futura&#39;s development pipeline focuses on sexual healthcare and pain relief management and we are evaluating further therapeutic opportunities as potential additions to the pipeline.

Andrew Unitt

Strategic Marketing Advisor at Futura Medical Developments

Simon. P. Pulsford

Non Executive Chairman at Foster+Freeman

Roy Davis

CEO at Futura Medical

James Barder

Futura Medical , is pleased to this morning announce its unaudited interim results for the six months ended 30 June 2024. The first half has seen a pleasing performance with the Group delivering revenue growth of 400% to £7.0m in FY24 H1 and a maiden profit after tax of £1.0m. Eroxon®, our breakthrough, safe and effective ED treatment gel is now being sold in stores and online in over ten countries, including key European markets such as France, Italy and Spain, with further launches already underway in H2, including in Mexico, the first Latin American country where Eroxon® is available. James Barder , Chief Executive Officer, commented: “It is a significant milestone to be able to announce our first profit, a year after the initial pilot launch of Eroxon®, and well ahead of market expectations. We believe that this is just the beginning for Eroxon®, our highly differentiated treatment for erectile dysfunction which helps users get an erection within ten minutes, as we look to build a new product and new category within the underserved sexual health market." “In the past year, Futura has transitioned from a loss-making R&D business to a profitable consumer healthcare company. This is a tremendously proud moment for me and the entire Futura team." “We look forward with excitement to the second half of 2024 with further launches already underway for Eroxon® and in particular the launch in the US, the largest consumer healthcare market in the world, by our distribution partner Haleon.” #FUM #menshealth #sexualhealth #erectiledysfunction Read the full announcement here: https://lnkd.in/eYpkncUM

Trinity Delta has yesterday published an Outlook Report on Futura Medical . The report notes that following the highly successful launch of #Eroxon ® in the UK and Belgium and with #Eroxon ® poised for launch in the key US market, Futura’s investment case has shifted firmly onto commercial execution. Please see below for the full report: https://lnkd.in/eJ3-UQ4A #FUM #menshealth #sexualhealth #erectiledysfunction

Futura Medical , is pleased to announce its final results for the year ended 31 December 2023 (“FY23”). This is a landmark set of results for the Group in which it has delivered its first meaningful revenues of £3.1m. In the year the Group made significant commercial progress following the launch of #Eroxon ® in the UK and Europe and signing Haleon as distribution partner in the US with preparation for launch going well. Our CEO, James Barder , commented: “Our team has worked tirelessly to get Futura to this point and we are incredibly excited for what’s to come. We have a lean operating model and clearly defined growth strategy, which underpins everything we do. The size of our target market and the early take up of #Eroxon ® in the markets where we have launched gives us great confidence as we look to make #Eroxon ® available to more people across the globe and on the path towards profitability in the next 12 months.” #FUM #menshealth #sexualhealth #erectiledysfunction Read the full announcement here: https://lnkd.in/eTXSJcce

Futura Medical is delighted to report that its lead product, #Eroxon ®, has won the Industry award for Consumer Healthcare at the ‘Consumer Healthcare Communication Awards 2023’, organized by Bachi, the industry association of OTC Healthcare companies in Belgium. This competition awards the best advertising campaigns for (non-reimbursed and non-prescription) healthcare products directed at consumers in the following three categories: • Most creative campaign • Most effective campaign • Campaign that best encourages the correct use of the product Winners are selected based on the votes of consumers, pharmacists and a professional jury, each representing 1/3 of the votes. #Eroxon ® was in the top 3 for all awards, and has taken home the award for Correct Use. We are delighted to see the work of our EEA, UK and Switzerland distribution partner Cooper Consumer Health being recognised, and the increasing awareness of #Eroxon ® across the markets where we have launched! #FUM #menshealth #sexualhealth #erectiledysfunction

Today Futura Medical is pleased to provide its trading update for the year ended 31 December 2023. FY23 was a transformational year for the Company as it delivered on the three key objectives it set itself for 2023: achieving regulatory approval in the US, the largest consumer healthcare market in the world; progressing commercial discussions by securing, in Haleon, a standout distribution partner there and reporting our first meaningful revenues of £3.1m. The first meaningful revenues generated from product sales and the broader success of the UK launch have been a catalyst for significant strategic progress across multiple markets. The launch, success of the partnerships and consumer take up of the product, clearly illustrates that Eroxon is helping to satisfy an unmet need in the market and highlights the scale of the opportunity across the globe. Our CEO, James Barder , commented: “With the size of the target market and the progress we are making to reach it, we look forward to the year ahead and confident of considerable growth acceleration over the medium term – delivering progress in sales across multiple countries and broadening distribution by launching in new markets.” Read the full announcement here: https://lnkd.in/erHgdiKx

James Barder , CEO of Futura, featured in Citeline Commercial 's HBW Insight, in its 'Consumer Health In 2024' article! Thanks to @David Ridley for including our contribution. Click the link below to read James' expectations for 2024 as we aim to build on what has been achieved to date and 'our success in addressing the needs of a growing number of erectile dysfunction sufferers'. Read more here: https://bit.ly/3S4v81g #FUM #menshealth #sexualhealth #erectiledysfunction

#FuturaMedical has extended its #collaboration with Cooper Consumer Health ! Extending the exclusive licensing agreement until January 2029 for the rights to commercialise #Eroxon ® throughout the European Economic Area, United Kingdom and Switzerland, is another significant step towards delivering our strategy and maximising value. Initial launches of Eroxon commenced in March 2023 in the UK and Belgium, with further launches across Europe during 2024, including the key markets of Italy, Spain, France and Germany. Find out more about the extended agreement here: https://lnkd.in/eEHNewmZ #FUM #menshealth #sexualhealth #erectiledysfunction

Today #FuturaMedical welcomes Roy Davis as a Non-Executive Director! Roy brings a wealth of commercial experience in medical devices companies and has a proven track record of successfully scaling companies and delivering substantial value for shareholders. Read the full announcement here: https://lnkd.in/ezNXZdij #FUM #menshealth #sexualhealth

🏆 We are pleased to share that #Eroxon is the winner of the Best Big Budget OTC Marketing Campaign Award at Citeline 's OTC Marketing Awards 2023! 🏆 Eroxon was also recognised as 'Highly Commended' in the following award categories: OTC Launch of the Year Most Innovative New OTC Product Best OTC Public Relations Campaign for a Consumer Healthcare Product Thank you to the Futura Medical team and our partners for their hard work and support over the past year. Congratulations to all other winners and finalists! #FUM #MensHealth #Sexualhealth #breakthroughproduct #globaldemand

Thank you to #OBN for nominating us as Best Established MedTech Company at the 2023 OBN (UK) Ltd Awards and congratulations to all winners and finalists! We would like to give a huge thank you and congratulations to the team at Futura Medical for the milestone achievements we have accomplished over the past year. #FUM #MensHealth #Sexualhealth #breakthroughproduct #globaldemand

COM:FUTURAMEDICAL

Futura Medical

Last Close

14.00

14/02 16:09

Market Cap

1.12M

Beta: -

Volume Today

480.89K

Avg: -

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

revenue

monthly webtraffic

monthly webtraffic growth

stage

raised capital

Description

competitor of

Metrics